NCT03976401 - A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

May 28, 2019

Primary Completion Date

February 10, 2021

Study Completion Date

January 10, 2022

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

EFX

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Trial Locations (27)

32127

Akero Clinical Study Site, Port Orange

33156

Akero Clinical Study Site, Miami

33434

Akero Clinical Study Site, Boca Raton

34211

Akero Clinical Study Site, Lakewood Rch

34240

Akero Clinical Study Site, Sarasota

34653

Akero Clinical Study Site, New Port Richey

34761

Akero Clinical Study Site, Ocoee

37421

Akero Clinical Study Site, Chattanooga

64131

Akero Clinical Study Site, Kansas City

70072

Akero Clinical Study Site, Marrero

70809

Akero Clinical Study Site, Baton Rouge

72117

Akero Clinical Study Site, Little Rock

75246

Akero Clinical Study Site, Dallas

76104

Akero Clinical Study Site, Fort Worth

77598

Akero Clinical Study Site, Webster

78215

Akero Clinical Study Site, San Antonio

78229

Akero Clinical Study Site, San Antonio

78539

Akero Clinical Study Site, Edinburg

78613

Akero Clinical Study Site, Cedar Park

85711

Akero Clinical Study Site, Tucson

90036

Akero Clinical Study Site, Los Angeles

90057

Akero Clinical Study Site, Los Angeles

90255

Akero Clinical Study Site, Huntington Park

91402

Akero Clinical Study Site, Panorama City

92064

Akero Clinical Study Site, Poway

08009

Akero Clinical Study Site, Berlin

00927

Akero Clinical Study Site, San Juan